Clairity Breast is the first FDA-authorized AI platform that predicts a woman’s five-year future risk of developing breast cancer, using only her existing screening mammogram.
“For more than 60 years, mammograms have saved lives by detecting early-stage cancers. Now, advancements in AI and computer vision can uncover hidden clues in the mammograms – invisible to the human eye – to help predict future risk. By delivering validated, equitable risk assessments, we can help expand access to life-saving early detection and prevention for women everywhere.”
Dr. Connie Lehman
AI is beginning to narrow a critical gap in breast cancer care. In February, Beth Israel Deaconess Medical Center (BIDMC) became the first medical center in the country to offer a new tool that uses artificial intelligence, coupled with a routine mammogram, to measure a patient’s future risk of breast cancer.
New guidelines from the National Comprehensive Cancer Network® champion artificial intelligence in breast cancer screening
Until now, understanding breast cancer risk outside of family history and BRCA mutations has been challenging. Innovations in AI technology might help predict cancer before it even takes root.
Clairity is launching soon at health systems across the USA. Sign up to be notified when it’s available at a health system near you.
